ArticleCureus2025
Assessment of Stromal Calretinin Expression in Normal and Pathological Endometrium of Patients With Abnormal Uterine Bleeding.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormal uterine bleeding (AUB) is a prevalent gynecological issue, often arising from structural or functional endometrial abnormalities. Calretinin, a calcium-binding protein, has demonstrated diagnostic relevance in various tissues; however, its role in endometrial stroma remains insufficiently explored. This study was conducted to evaluate calretinin expression in normal and pathological endometrial tissues associated with AUB. MATERIALS AND
methodsA prospective observational study was conducted on 60 endometrial samples (normal and AUB-associated lesions) over two years from June 2023 to March 2025. Histopathological evaluation was followed by immunohistochemistry for stromal calretinin using a semi-quantitative score (0-5+). Statistical analysis was performed using IBM SPSS Statistics v25.0 (IBM Corp., Armonk, USA), including analysis of variance (ANOVA), Tukey's post hoc test, and Pearson's correlation.
resultsNormal endometrium (notably secretory and proliferative phases) exhibited higher stromal calretinin expression (mean scores: 3.0 and 2.0, respectively), while lesions such as adenomyosis, endometrial polyps, hyperplasia, and carcinoma demonstrated markedly reduced or absent expression. A statistically significant difference in calretinin scores was found across different histopathological categories (p=0.0002). A moderate negative correlation (r=-0.43) was observed between calretinin expression and pathological endometrial states.
conclusionStromal calretinin expression was substantially reduced in AUB-related endometrial lesions compared to normal endometrium. These findings suggest its potential utility as a supplementary biomarker for distinguishing between physiological and pathological endometrial conditions. Further large-scale studies are warranted to validate its diagnostic and prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.